India's Bajaj Healthcare hits record high as seizure drug trial gets regulatory nod

Bajaj Healthcare

19/03/2025 07:49

** Shares of Bajaj Healthcare BAJH.NS rise as much as 10.3% to hit record high at 745 rupees

** The pharmaceutical co says its has secured SEC-CDSCO nod for Phase III clinical trials of anti-seizure medication Cenobamate tablets

** Phase III clinical trials are the final stage of drug development before regulatory approval - BAJH

** Stock on track for a third consecutive session of gain, if trend holds

** Stock is witnessing its most active trading session since January 29, with more than 1.3 mln shares changing hands, 3.3x of 30-day avg

** Stock last up 6%, taking YTD gains to 25%

 (Reporting by Ashish Chandra in Bengaluru)

 ((ashish.chandra@thomsonreuters.com (+91 7982114624))